Heparan Sulfate Domains Required for Fibroblast Growth Factor 1 and 2 Signaling through Fibroblast Growth Factor Receptor 1c by Schultz, Victor et al.
Heparan Sulfate Domains Required for Fibroblast Growth
Factor 1 and 2 Signaling through Fibroblast Growth Factor
Receptor 1c*
Received for publication,October 3, 2016, and in revised form, December 16, 2016 Published, JBC Papers in Press,December 28, 2016, DOI 10.1074/jbc.M116.761585
Victor Schultz‡, Mathew Suflita§, Xinyue Liu‡, Xing Zhang‡, Yanlei Yu‡, Lingyun Li¶, Dixy E. Green,
Yongmei Xu**, Fuming Zhang‡, Paul L. DeAngelis, Jian Liu**, and Robert J. Linhardt‡§‡‡§§1
From the Departments of ‡Chemistry and Chemical Biology, §Biology, ‡‡Biomedical Engineering, and §§Chemical and Biological
Engineering, Rensselaer Polytechnic Institute, Troy, New York 12180, the ¶Wadsworth Center, New York State Department of
Health, Albany, New York 12201, the Department of Biochemistry andMolecular Biology, University of OklahomaHealth Sciences
Center, Oklahoma City, Oklahoma 73126, and the **Division of Chemical Biology andMedicinal Chemistry, Eshelman School of
Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599
Edited by Gerald W. Hart
A small library of well defined heparan sulfate (HS) polysac-
charides was chemoenzymatically synthesized and used for a
detailed structure-activity study of fibroblast growth factor
(FGF) 1 and FGF2 signaling through FGF receptor (FGFR) 1c.
The HS polysaccharide tested contained both undersulfated
(NA) domains and highly sulfated (NS) domains as well as very
well defined non-reducing termini. This study examines differ-
ences in the HS selectivity of the positive canyons of the FGF12-
FGFR1c2 and FGF22-FGFR1c2 HS binding sites of the symmet-
ric FGF2-FGFR2-HS2 signal transduction complex. The results
suggest that FGF12-FGFR1c2 binding site prefers a longer NS
domain at the non-reducing terminus than FGF22-FGFR1c2. In
addition, FGF22-FGFR1c2 can tolerate an HS chain having an
N-acetylglucosamine residue at its non-reducing end. These
results clearly demonstrate the different specificity of FGF12-
FGFR1c2 and FGF22-FGFR1c2 for well defined HS structures
and suggest that it is now possible to chemoenzymatically syn-
thesize precise HS polysaccharides that can selectively mediate
growth factor signaling. These HS polysaccharides might be
useful in both understanding and controlling the growth, prolif-
eration, anddifferentiationof cells in stemcell therapies,wound
healing, and the treatment of cancer.
Heparan sulfate is a glycosaminoglycan (GAG),2 a linear sul-
fated polysaccharide of 134-linked -D-glucosamine (GlcN)
and uronic acid, -D-glucuronic acid (GlcA), or -L-iduronic
acid (IdoA) (1). Themammalian GAGheparan sulfate contains
a domain structure comprising undersulfated sequences rich in
GlcNAc (where Ac is acetyl) residues (called “NA domains”)
and highly sulfated sequences rich in GlcNS (where S is sulfo)
residues (called “NS domains”) (Fig. 1) (2–4). These domains
structurally vary based on the species and tissues fromwhich an
HS is obtained (5), and the NS domain is of particular impor-
tance in cellular behavior and disease processes (6). HS is bio-
synthesized in the endoplasmic reticulum and Golgi as a con-
stituent of proteoglycans (PGs) attached to one of a number of
core proteins (7, 8). The biosynthesis of the GAG chain within
the Golgi controls the placement of domains within HS (8, 9).
These PGs are primarily localized to the cell membrane or in
the extracellular matrix (7, 8) where they play a critical biolog-
ical role as a co-receptor in growth factor signaling (10, 11). HS
domain structure and position on the GAG chain can also be
catabolically modified through the action of extracellular sulfa-
tases (7, 12) and heparanase (7, 13). A plethora of HS structures
are possible, and many are observed in animals.
In the past, heparan sulfate used in biochemical studies was
generally extracted from animal tissues following proteolysis.
The resulting HS GAG is large (Mr10,000), polydisperse (for
Mr 10,000–30,000, weight average molecular weight/number
average molecular weight values of 1.2–1.6), and microhetero-
geneous (e.g. possessing multiple structural domains and vari-
able saccharide sequences) (5, 14, 15, 17). The structural com-
plexity of heparan sulfate GAG complicates the study of its
structure-activity relationship (SAR) with regard to its protein-
mediated signaling activities. Related less heterogeneous and
more highly sulfated heparin, chemically modified heparins, or
heparin-derived oligosaccharides have been applied to simplify
these SAR studies (18–21). Unfortunately, natural heparan sul-
fate has highly variable compositions and sequences, and only a
very limited number of chemically modified heparin structures
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FIGURE 1. Structures of natural and synthetic heparan sulfates. A generalized chemical structure of animal-sourced HS is shown, and below it the same
structure is drawn using conventional symbols (59). Synthetic heparan sulfates 1-8 are shown in their symbolic representations. The presence of substituents
is indicated above and below the symbols with the carbon position number (or “N” for nitrogen substituent) and “OH” for unsubstituted or “S” for sulfo group
substituted. An “OH/S” indicates that the position can be either unsubstituted or sulfated. The “/” at the non-reducing terminus indicates an ambiguous
monosaccharide that was not controlled during the final step of synthesis.
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can be reliably prepared from natural polysaccharides and in
quite small quantities (e.g. micrograms to milligrams). Struc-
turally defined heparan sulfate-derived or heparin-derived
oligosaccharides from natural GAGs or organic synthesis are
often too small to exhibit many important biological activities
in comparisonwith the “full-length” native polysaccharides (18,
19, 21).
Recently, it has become possible to chemoenzymatically syn-
thesize larger heparan sulfate chains having domain structures
(22). Recombinant heparan sulfate-polymerizing and -modify-
ing enzymes have been utilized for reactions in vitro (23–25).
The GAG chain backbones can be efficiently and controllably
synthesized in vitro using GAG synthases to add the monosac-
charide units fromUDP-sugar donors onto an acceptor (Fig. 2).
When buildingGAGs fromnatural UDP-sugars (UDP-GlcNAc
and UDP-GlcA) or non-natural UDP-sugars (UDP-GlcNTFA
where TFA is trifluoroacetyl) (26), in vitroGAGchain synthesis
can be performed in one of two preferred formats: stepwise
elongation (i.e. one sugar unit at a time) or in a synchronized
polymerization reaction (i.e. block addition via multiple sugar
units). Both of these formats yield well defined products with
narrow size distributions (monodisperse or nearly so) and
potentially much more controllable compositions than the
GAG produced in vivo (21, 27–29).
In our approach, the polysaccharide backbone is assembled
with blocks of either (34)--D-GlcA (134)--D-GlcNAc(13)
or (34)--D-GlcA (134)--D-GlcNTFA(13). Mild chemical
treatments remove theTFAmoieties from the glucosamine and
replace it withN-sulfo groups to generate a precursor structure
with blocks of (34)--D-GlcA (134)--D-GlcNAc(13) or
(34)--D-GlcA (134)--D-GlcNS(13) that are enzymatically
modified with C5-epimerase, which converts GlcA into IdoA,
and O-sulfotransferases that transfer sulfo groups from the
donor 3-phosphoadenosine 5-phosphosulfate (PAPS) to the
various hydroxyl groups of the GAG (30–36). Such resulting
synthetic heparan sulfate chains have a controlled domain
structure useful for SAR studies (22).
Heparan sulfate regulates the activity of the 22-member fam-
ily of extracellular fibroblast growth factors (FGFs) involved in
critically important cellular activities including angiogenesis,
cellular proliferation, cellular motility, differentiation (37–39),
and adhesion (40, 41). The FGFs signal through their cognate
membrane-bound fibroblast growth factor receptors (FGFRs),
a group of seven distinct protein receptors (42–44), and an HS
co-receptor. Kinetic experiments using surface plasmon reso-
nance suggest that two extracellular FGFs first bind to the HS
chain(s) of membrane-anchored HSPGs and then recruit two
FGFRs to assemble into a signaling complex (45). Assembly of
an FGF-HS-FGFR ternary complex (46) then activates signaling
across the transmembrane helix, which then activates the intra-
cellular tyrosine kinase domain (47). The individual binding
affinities of theHS chains for FGFs and FGFRs have been deter-
mined, but the actual structure of the ternary complex remains
unclear (45, 48–52). The dimeric protein complex, FGF2-
FGFR2, forms a positively charged cleft or “canyon” lined with
basic amino acid residues that interact with one or two comple-
mentary negatively charged HS chains with high (nM range)
affinity (43, 53, 54). The FGF-HS-FGFR ternary complex is
believed to be a symmetric structure of 2:2:2 stoichiometry (55).
Previous studies show that highly sulfated NS domains at the
non-reducing terminus of heparan sulfate bind with higher
affinity and promote FGF2-FGFR1 signaling (22, 56).
The current study examines the impact of the domain struc-
ture and the structure at the non-reducing terminus of che-
moenzymatically synthesized heparan sulfate GAG chains on
FGF-1 and FGF-2 signaling through FGFR-1c. Heparan sulfate-
mediated FGF-FGFR signaling was determined using a murine
immortalized bone marrow (BaF3) cell line developed by
Ornitz and co-workers (43, 54) that expresses FGFR type 1c
without expressing either HSPGs or FGF. The ternary complex
signaling process is determined by measuring heparan sulfate-
mediated cellular proliferation.
Results
Design of Synthetic Heparan Sulfate Targets for Testing—The
domains present within natural heparan sulfate consist of
sequences of high sulfation (NS domains) and low sulfation
(NA domains) (2–4). Although these domains vary in size and
number of sulfo groups among species and tissues (5), the
regions do share some common features. First, their placement
and sizes are believed to be controlled through the placement of
N-sulfo groups by the action of the different N-deacetylase
N-sulfotransferase isoforms (3, 4, 8, 9, 11, 30). Second, the
domain closest to the core protein at the reducing end of the
heparan sulfate chain is generally an NA domain, whereas
the domains at the non-reducing end of non-signaling and sig-
naling heparan sulfate chains are typically NA andNS domains,
respectively (2, 4). Moreover, the conversion of a non-signaling
heparan sulfate chain to a signaling heparan sulfate chain in
disease processes associated with rapid cell proliferation, such
as cancer, can also take place through the action of heparanase,
which cleaves between a high and low sulfate domain, thus
exposing a GlcN residue associated with an NS domain at the
non-reducing end of the chain (7, 13).
Eight heparan sulfate chains were designed to begin to study
the contribution of domain structures in HS for FGF-FGFR
signaling (Fig. 1, 1-8). These chains consist of one or two long
domains assembled at the non-reducing end of a GlcA-pNP
acceptor. One chain, 2, contained a long (28-disaccharide
repeat) NS domain assembled at the non-reducing end of a
GlcA-pNP acceptor, resembling heparin, serving as a positive
control in signaling assays. A second chain, 1, contained a long
(15-repeat) NA domain assembled at the non-reducing end
of the acceptor (Fig. 3), resembling a single domain heparan
sulfate chain, serving as a negative control in signaling assays. A
third chain, 3, contained two domains comprising a long (13-
repeat)NS domain assembled at the non-reducing end of a long
(15-repeat) NA domain assembled at the reducing end of the
GlcA-pNP acceptor. On the remaining five synthetic heparan
sulfate chains (4-8), this long (16-repeat) reducing end NA
domain was terminated at the non-reducing end with NS
domains of variable lengths capped with a single GlcN residue
substituted with either an N-sulfo or N-acetyl group.
Block Copolymer Elongation and Formation—Chain synthe-
sis began on a commercially available GlcA-pNP acceptor. This
acceptor was iteratively extended through the alternative addi-
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FIGURE 2. Chemoenzymatic synthesis of heparan sulfates. The first step involving the iterative synthesis of the trisaccharide acceptor from GlcA-pNP and
UDP-donor sugars is not shown. a, the second step is polysaccharide backbone synthesis from the trisaccharide acceptor andUDP-donor sugars (shown at the
top) under stoichiometric control. b, the chemical conversion of GlcNTFA to GlcN (for a GlcNAc-containing domain, this part of the chain remains basically
untransformed at this step). c, the chemical conversion of GlcN to GlcNS. d, enzymatic treatment with C5-epimerase and 2-O-sufotransferase. e, enzymatic
treatment with 6-O-sufotransferase 1 and 6-O-sufotransferase 3.
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FIGURE3.PAGEanalysis of various synthetic heparosanandTFA-protectedheparosanprecursors andHPLC-MSanalysis of theprecursor to synthetic
heparan sulfate 1. The heparosan polysaccharide and TFA-protected heparosan precursorswere assembled on theGlcA-GlcNAc-GlcA-pNP orGlcA-GlcNTFA-
GlcA-pNP acceptors analyzed by HPLC-MS. A, 8% PAGE was used to analyze these samples together with individual hyaluronan and a mixture of hyaluronan
(HA) standards (Hyalose, LLC; note that hyaluronan and heparosan migrate similarly but not identically on PAGE). Samples (1 g) were loaded onto the gel
and run at 250V applied for 20min. The gelwas stainedovernightwith 0.05%Alcian Blue stain. Lane 1, hyaluronan LoLadder (fastestmigratingband is 27 kDa);
lanes 2 and 13, 10-kDahyaluronan; lanes 3 and 12, 6.5-kDahyaluronan; lane 4, NAcprecursor of1; lanes 5 and 11, NAcprecursor of1 (SAX-polished); lane 6, NTFA
precursor of 4 (five sugars added); lane 7, NAc precursor of 7 (nine sugars added); lane 8, NTFA precursor of 5 (nine sugars added); lane 9, NAc precursor of 8 (11
sugars added); lane 10, NTFA precursor of 6 (11 sugars added). HPLC-MS analysis of the precursor to synthetic heparan sulfate 1 (purified; same as shown in A,
lanes 5 and 11) was performed. B, the HPLC chromatogramwith the broad peak at 6.94min corresponding to the polysaccharide chain. C, the mass spectrum
of polysaccharide chains in the HPLC peak eluting at 6.94min.D, the deconvolutedmass spectrum of polysaccharide chains in the 6.94-min HPLC peak with a
degree of polymerization (dp; the number of monosaccharides in the chain) and molecular mass distribution of precursor to synthetic heparan sulfate 1
showing a molecular mass consistent with the 6.4-kDa target.
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tion of UDP-GlcNAc and UDP-GlcA donors to prepare the
precursor for targets 1 and 3-8 or UDP-GlcNTFA and UDP-
GlcAdonorstoprepareprecursorfortarget2,resultingintrisac-
charides GlcA-GlcNAc-GlcA-pNP andGlcA-GlcNTFA-GlcA-
pNP. These trisaccharides were characterized by electrospray
ionization mass spectrometry (MS) and anion exchange high
performance liquid chromatography (HPLC).
The synthesized trisaccharides are excellent acceptors for
stoichiometrically controlled extension. The length of the long
domainwas controlled by the ratio of the trisaccharide acceptor
and the UDP-sugar donors. The molecules are quasimonodis-
persedue to the synchronizationof the synthase-catalyzedpoly-
merization reaction with acceptor as described (27). The size of
the resulting chains, (GlcA-GlcNAc)15-GlcA-pNP (as well as
all the other synthetic HS chains), was determined by HPLC-MS.
The (GlcA-GlcNTFA)28-GlcA-pNP chain corresponds to the first
precursor to synthetic heparan sulfate 2 (Figs. 1 and 4, top).
The (GlcA-GlcNAc)16-GlcA-pNP chains were further mod-
ified by iterative transfer of UDP-GlcNTFA and UDP-GlcA
adding five, 9, or 11 additional monosaccharide units. In each
case, these chains were cappedwith either a final GlcNTFA or a
GlcNAc residue (Fig. 1) to afford the first precursor of the
designed synthetic heparan sulfates 4-8. It is important to note
that these non-reducing terminal extensions were completely
defined structures. Although there are multiple species (8
major) observed for the block portion of the synthetic chain, the
stepwise synthesis results in precise additions. This control is
needed to assess the SAR of the end of HS chains.
Glucosamine De-N-trifluoracetylation and N-Sulfonation—
Once the precursors to synthetic heparan sulfates2-8were syn-
thesized with the desired GlcNAc- and GlcNTFA-containing
domains, theNTFA groupswere deprotected and subsequently
N-sulfonated. Each TFA-containing block copolymer was dis-
solved in a mildly basic solution of Et3N, MeOH, and H2O and
stirred overnight. Under these conditions, the GlcNTFA resi-
dueswere completely deprotected, exposing free amino groups,
which were chemicallyN-sulfonated using NMe3SO3 to afford
GlcNAc and GlcNS domains containing block copolymers, the
NSulfo precursors to synthetic heparan sulfates 2-8. Con-
versely, the acetyl groups ofNAdomains remain virtually intact
throughout this process.
The sizes of the resulting dicopolymer intermediates, as
examined using polyacrylamide gel electrophoresis (PAGE)
and LC-MS,were consistentwith those expected based on their
synthesis. The disaccharide composition of the NSulfo precur-
sors to synthetic heparan sulfates 4, 5, 6, and 7 were examined
by disaccharide compositional analysis using HPLC-MS analy-
sis to confirm that the expected extensions had taken place
(Table 1).
The structure of the NTFA and NSulfo precursors for each
synthetic heparan sulfate was evaluated by one-dimensional
(1D) 1Hnuclearmagnetic resonance (NMR).The 1H spectra for
the NTFA andNSulfo precursors of synthetic heparan sulfate 2
are shown in Fig. 4. The conversion of the GlcNTFA residue to
a GlcNS residue was confirmed by the change in chemical shift
of the anomeric proton (H1) signal. NMR spectra of all block
copolymers show two signals in the anomeric region of4–6
ppm. The signals at 5.5 and 4.4 ppm correspond to the
anomeric proton of GlcNTFA and GlcA, respectively. Incom-
plete N-sulfonation would be indicated by a peak at5.6 ppm,
but such a signal cannot be seen in the spectra. Taken together,
theNMRdata indicate that the block copolymers were success-
fully N-sulfonated.
Disaccharide Composition of Heparan Sulfate Precursors—
The disaccharide composition of the heparan sulfate NSulfo
was next determined by exhaustively treating eachwith heparin
lyases, labeling with 2-aminoacridone (AMAC), and perform-
ing HPLC-MS. The resulting total ion chromatogram obtained
FIGURE 4.NMRanalyses ofHS intermediates.ProtonNMR (600MHz) of the first and second intermediate products of synthetic heparan sulfate2was carried
out. Top, theNTFAprecursor, corresponding to compound2. Bottom, theNSulfo precursor is formed throughde-N-trifluoracetylation andN-sulfonation of the
NTFA precursor.
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by HPLC-MS analysis showed only 0S and NS disaccharides
associated with each of the HS block copolymers. The
HPLC-MS analysis of theNSulfo precursor of heparan sulfate 4
shown in Fig. 5, for example, is consistent with its structure
after compensating for the different response factors for the 0S
and NS disaccharides. The experimentally observed disaccha-
ride compositions of the NSulfo precursor of heparan sulfates
4-7, which have a complex block structure, correspond quite
well to their theoretical compositions (Table 1). The data sug-
gest that these polysaccharide compounds have the anticipated
structures.
C5-Epimerization and O-Sulfonation—The HS block copo-
lymers were treated exhaustively with C5-epimerase in the
presence of 2-O-sulfotransferase followed by 6-O-sulfotrans-
ferase 1 and 6-O-sulfotransferase 3. These enzymes all act in the
N-sulfo domains to form fully modified high sulfo S-domains
comprising3GlcNS6S3 IdoA2S3 repeating units. The 6-O-
sulfotransferases could also modify the N-acetyl N-domains to
a limited extent.
Characterization of Heparan Sulfate Products—The disac-
charide composition of the synthetic heparan sulfates obtained
through C5-epimerization and O-sulfonation were next ana-
lyzed by LC-MS (Fig. 2 and Table 1). The disaccharide analysis
of synthetic heparan sulfate 4 is shown in Fig. 5. Upon treat-
ment with heparin lyases, all the synthetic heparan sulfates
afforded complexmixtures containing different amounts of the
eight possible disaccharides (Table 1). The NS domains com-
prised TriS and NS6S, consistent with expectation. The NA
domains primarily comprised 0S, 2S, and 6S. High levels of
0S and 6S were anticipated. The exhaustive treatment of NA
domains with C5-epimerase in the presence of 2-O-sulfo-
transferase affording surprising amounts of 2S-containing
sequences is most likely the result of the presence of unex-
pectedly large amounts of GlcA2S.
Bioactivity/Cellular Proliferation of Synthetic Heparan
Sulfates—The synthetic heparan sulfates were tested for cellu-
lar proliferation with the FGFR1c-expressing cells in the pres-
ence of FGF1 or FGF2 in a 96-well plate (22). The assay was
performed in a single 96-well plate in triplicate, giving a small
standard deviation, confirming the precision of this measure-
ment. First, a standard curve of the optical density (at 590 nm)
as a function of y was constructed to demonstrate the linearity
of the cellular proliferation assay (Fig. 6A). The negative con-
trol, no added heparan sulfate, gave a baseline cell count of
4,000  750 and 33,000  1,100 for FGF1 and FGF2 signaling
through FGFR1c, respectively (Fig. 6B). The difference in base-
line may be an indication that FGF2may promote some signal-
ing in the absence of GAG, although signaling is greatly aug-
mented by addition of these polysaccharides. Porcine intestinal
mucosal heparin served as a positive control, showing a cell
count of 26,000 1,900 throughFGF1but a significantly higher
cell count of 49,000 990 through FGF2. Next, porcine intes-
tinal heparan sulfate was tested, and although it showed a very
low cell count of 7,000  460 through FGF1, it unexpectedly
showed a slightly higher signaling cell count of 52,000 1,400
than observed for heparin through FGF2. This observation
implies potential for the variability for naturally sourcedGAGs.
As expected, synthetic heparan sulfate 2 containing only a
single NS domain with28 repeating disaccharides and termi-
nated with a GlcNS residue at the non-reducing end showed
high FGF1 and FGF2 signaling activities (26,000  330 and
49,000  2,600, respectively) similar to that observed for hep-
arin. Similarly, the two-domain synthetic heparan sulfate3with
an NA domain of15 repeating disaccharides at the reducing
end and an NS domain of 15 repeating disaccharides at the
non-reducing end also showed potent FGF1 and FGF2 signal-
ing activities (26,000 2,600 and 57,000 3,200, respectively)
comparable with the positive control heparin. Synthetic hepa-
ran sulfate 1 having a singleNAdomain of15 repeating disac-
charides and terminated with a GlcA residue showed no FGF1
and FGF2 signaling activities (i.e. buffer alone baseline values),
suggesting that a non-reducing terminal NS domain is critical
for robust signaling.
Of particular interest were the signaling activities of syn-
thetic heparan sulfates 4-8 having an NA domain of 16
repeating disaccharides (derived from 1, the inactive HS) at the
reducing end with defined short variable length NS domains at
their non-reducing ends. Synthetic heparan sulfates 7 and 8
with a reducing endNAdomain of16 repeating disaccharides
and non-reducing end NS domains of four and five repeating
disaccharides were terminated with a GlcNAc residue. Syn-
thetic heparan sulfates 7 and 8 behave similarly to synthetic
TABLE 1
Disaccharide composition of the precursors and the oligosaccharides after O-sulfation
Disaccharide composition was calculated fromHPLC-MS peak integration (Fig. 4) using appropriate response factors. The theoretical percentage of dp2(NS) (where dp is
the degree of polymerization) was calculated as NS/(NSNAc 1), and the percentage of dp2(NAc) was calculated as (NAc 1)/(NSNAc 1) (see structure in Fig.
1). TriS, NS6S, NS2S, and NS disaccharides arise from the NS domains, and 2S6S, 6S, 2S, and 0S disaccharides arise from the NS domains. —, not detected.
Disaccharide composition Experimental Theoretical










NSulfo precursor 4 — — — 17 — — — 83 17 83 12 88
NSulfo precursor 5 — — — 26 — — — 74 26 74 21 79
NSulfo precursor 6 — — — 30 — — — 70 30 70 25 75
NSulfo precursor 7 — — — 28 — — — 72 28 72 21 79
Heparan sulfate 1 — 16 — — — 7 — 77 16 85 0 100
Heparan sulfate 2 65 23 — — — 1 7 3 88 11 100 0
Heparan sulfate 3 37 15 — — — 10 3 36 52 49 48 52
Heparan sulfate 4 2 6 — — — 15 32 44 8 91 12 88
Heparan sulfate 5 6 14 — — — 21 17 41 20 79 21 79
Heparan sulfate 6 5 14 — — — 19 29 31 19 79 25 75
Heparan sulfate 7 5 12 — — — 21 23 39 17 83 21 79
Heparan sulfate 8 — 20 — — — 17 — 63 20 80 25 75
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heparan sulfate 1, showing no FGF1 signaling activities. Inter-
estingly, synthetic heparan sulfates 7 and 8 showed some FGF2
signaling activity. Synthetic heparan sulfates 4, 5, and 6 with
non-reducing end NS domains of two, four, and five disaccha-
rides and terminated with a GlcNS residue showed differential
FGF1 and FGF2 signaling activities. Synthetic heparan sulfates
5 and 6 with longer four- and five-disaccharide non-reducing
end NS domains showed low FGF1 and high FGF2 signaling
activities. In contrast, synthetic heparan sulfate 4 with the
shortest non-reducing end NS domain showed no FGF1 and
FGF2 signaling activities, suggesting that a non-reducing end
terminal NS domain of at least four to five disaccharides is nec-
essary for signaling. The BaF3 cell-based assay was performed a
second time and confirmed the relative similar levels of signal-
ing for the various synthetic heparan sulfates.
Discussion
Using our chemoenzymatic approach for the synthesis of
heparan sulfate polysaccharides on simple aglycone acceptors,
we had previously synthesized block polysaccharides having
different arrangements of uniform size NS and NA domains
(22). The symmetric FGF2-HS2-FGFR2 ternary complex model
(55) was best supported by the results of our prior study sug-
gesting thatNSdomains at the non-reducing endwere required
for FGF signaling (22). Because of the topological constraints of
the two heparan sulfate chains being attached to the core pro-
tein through their reducing ends (in the native FGF2-HSPG2-
FGFR2 complex the two heparan sulfate chains are attached to
the core protein through their reducing ends), the interacting
NS domains must be located on the non-reducing end of each
FIGURE 6. Fibroblast growth factor receptor bioactivity of natural and
synthetic HS. Heparan sulfate-mediated FGF-FGFR signaling was analyzed
using a BaF3 cellular proliferation assay in a 96-well plate (22). A, FGF1 signal-
ing through FGFR1c. The inset shows a standard curve of cell proliferation
assay. B, FGF2 signaling through FGFR1c. Abs, absorbance; Ctrl, control; HP,
heparin. Error bars represent S.D.
FIGURE 5. Disaccharide compositional analysis of synthetic HS. Disaccharides afforded through treatment with heparin lyases I, II, and III were analyzed
using HPLC-MS. Extracted ion chromatograms (EIC) are shown on the left, and mass spectra are shown on the right (0S, before any modification; NS, after
N-sulfonation; and TriS, after O-sulfation.) A, HPLC analysis of heparan sulfate disaccharide standards with detection by an ion trap mass spectrometer. B,
disaccharide analysis of the NSulfo precursor intermediate for synthetic heparan sulfate 4. C, disaccharide analysis of synthetic heparan sulfate 4 (complete
with O-sulfotransferase modifications).
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heparan sulfate chain (Fig. 7). These two heparan sulfate chains
are docked through their non-reducing ends into the basic can-
yon located on the top face of the FGF2-FGFR2 protein complex
called the heparin binding site. Furthermore, the electrostatic
and topological characteristics of the basic canyon are different
for each protein signaling complex; i.e. the canyon of FGF12-
FGFR1c2 should be distinct from that of FGF22-FGFR1c2 (57).
Most SAR studies in the past focused on the structural char-
acteristics of heparin or HS required for binding to various
FGFs in the absence of receptor (58). These studies provide only
limited information because they do not consider the FGFR
component of the interaction (57). Furthermore, without a cel-
lular component, such as used in the BaF3 assay, it is always
unclear whether binding is sufficient for signaling (49). Bio-
chemical studies directly assessing FGF-FGFR signaling clearly
support the symmetric FGF2-HS2-FGFR2 ternary complex
model in which the non-reducing ends of two HS chains are
involved in the interaction (22, 52, 60). Studies on chemically
modified heparins and various chondroitin sulfates generally
show heparin giving the greatest signaling among the heparin
derivatives and dermatan sulfate (chondroitin sulfate B) giving
the greatest signaling for the various chondroitin sulfates (61).
Although these previous studies provide a better understanding
of the SAR, they provide no information about the precise
structural features directly at the non-reducing ends of the
chains involved in FGF signaling.
FGF2 signaling through FGFR1c has been shown to interact
via the NS domains of HS chains (62) and FGF2 binding to
FGFR1c (57). The current study is focused on developing a
more precise SAR for heparan sulfate-mediated signaling
through one pair of homologous growth factor-receptor com-
plexes, FGF12-FGFR1c2 and FGF22-FGFR1c2. A new paradigm
for the chemoenzymatic synthesis of a variety of larger heparan
sulfate chains having between 16 and 28 repeating units was
required to carry out this study.
Our synthetic approach utilized three enzymatic steps using
UDP-sugar donors to build the polysaccharide backbone. In the
first step, a commercially available glycoside acceptor, GlcA-
pNP, was iteratively extended to the heparosan trisaccharide
acceptor GlcA-GlcNAc-GlcA-pNP or GlcA-GlcNTFA-GlcA-
pNP. In the second step, the trisaccharide acceptors were effi-
ciently elongated through stoichiometrically controlled exten-
sion to afford either an NA block or the NTFA precursor of an
NS block. In the third step, either a second block was added
under stoichiometric control, or a short oligosaccharide
domain was added through iterative synthesis. For the end-
capped polymers, the last residue added at the non-reducing
end of the chain was controlled to be either GlcNAc or
GlcNTFA.
Once the suitable polysaccharide precursors were assem-
bled, the GlcNTFA residues were quantitatively converted to
GlcNS as could be demonstrated by NMR and through the use
of HPLC-MS-based disaccharide analysis. It is important to
note that, in comparison with the naturalN-deacetylaseN-sul-
fotransferase-based processes, our strategy for chemical instal-
lation of the NSulfo groups (i) is virtually complete and (ii)
FIGURE 7. Proposed model and structure/activity relationship of heparan sulfate-mediated FGF-FGFR signaling through an FGF2-HSPG2-FGFR1c2
complex. Heparan sulfate structural characteristics required to facilitate signaling complex formation differ between FGF1 and FGF2. FGF1 (left) requires a
terminal NS domain of 10–11 disaccharides and a terminal GlcNS for signaling. In contrast, FGF2 (right) utilizes a shorter non-reducing NS domain (5
disaccharides) and is tolerant of a non-reducing end GlcNAc.
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allows strict placement and segregation of the NA and NS
domains.
Final enzymatic treatment with C5-epimerase and 2-OST
followed by 6-OST-1 and 6-OST-3 afforded synthetic heparan
sulfates 1-8. After confirming their structures, a 96-well plate
BaF3 cell proliferation assay was conducted to afford a more
detailed SAR of heparan sulfate signaling through FGF12-
FGFR1c2 or FGF22-FGFR1c2.
The heparan sulfate binding site canyon in FGF12-FGFR1c2
appears to prefer a longer non-reducing terminal NS domain
than that of FGF22-FGFR1c2 (Fig. 7). Porcine intestinal heparin
strongly signals through FGF12-FGFR1c2 as do synthetic hepa-
ran sulfates 2 and 3, but porcine intestinal heparan sulfate and
synthetic heparan sulfate6 onlyweakly signal. This suggests the
minimum NS binding domain to be four to five disaccharide
repeats terminatedwith aGlcNS residue for weak signaling and
an NS binding domain of 15 disaccharide sequences termi-
nated with a GlcNS for robust signaling. In contrast, the hepa-
ran sulfate binding site canyon in FGF22-FGFR1c2 appears to
utilize a shorter non-reducing terminal NS domain. Robust sig-
naling was observed for synthetic heparan sulfates 5 and 6, but
no signaling was observed for 4, suggesting that the optimal
length of the non-reducing terminal NS domain is4–5 disac-
charides with a terminal GlcNS residue. Furthermore, in con-
trast to FGF12-FGFR1c2, signaling was observed for synthetic
heparan sulfates 7 and 8 with a non-reducing terminal NS
domains of four and five disaccharides, respectively, with a ter-
minal GlcNAc residue, demonstrating flexibility in the require-
ment for terminal NS domains.
The results of this study demonstrate that, at least for
the FGF12-FGFR1c2 and FGF22-FGFR1c2 signal transduc-
tion complexes, it is possible to design and chemoenzymatically
synthesize heparan sulfates that can selectively mediate signal-
ing. Basically, in this case, our HS species with shorter NS ter-
minal domains allow differential targeting of one FGF signaling
complex over another homologous complex. The application of
this approach to the other 20 members of the FGF family and
the other six FGFRs needs to be explored. Ultimately, the use of
synthetic heparan sulfates to selectively control FGF-FGFR sig-
naling might play an important role in the control of stem cell
differentiation or developmental biology and might suggest
new therapeutic approaches for the treatment of cancer and
enhancement of wound healing.
Experimental Procedures
Materials—Triethylamine, trimethylamine-sulfur trioxide
complex, endotoxin-free water, carbazole, MES, HEPES,
AMAC, dimethyl sulfoxide (DMSO), sodium cyanoborohy-
dride, and DEAE-Sepharose were from Sigma-Aldrich. D2O
(99.9%) and Norell Select Series 5-mm NMR tubes were pur-
chased from Sigma-Aldrich and used directly from packaging.
Ammonium acetate (NH4Ac), calcium chloride (CaCl2), acetic
acid (HAc), Whatman 3MM paper, n-butyl alcohol, and HPLC
grade acetonitrilewere fromFisher Scientific.Hyaluronan stan-
dards for PAGE were obtained from Hyalose, LLC (Oklahoma
City, OK). All other chemical reagents were purchased from
Sigma-Aldrich and used without further purification.
The Chimera G bifunctional heparosan polymerizing
catalyst was a fusion of maltose-binding protein (MBP) to
PmHS2(1–167)-PmHS1(134–318)-PmHS2(353–651) prepared
in recombinant Escherichia coli as described previously (63).
Two mutant monofunctional derivatives of MBP-Chimera G
that transfer either UDP-GlcA (D479N,D481N in PmHS2
sequence) or UDP-GlcNAc (D181N,D183N in PmHS1 se-
quence) were constructed by site-directed mutagenesis in an
analogous process to PmHS1 (64). UDP-GlcA, UDP-GlcNAc,
and GlcA-pNP were purchased from Sigma unless otherwise
noted. UDP-GlcNTFAwas chemoenzymatically synthesized as
described previously (26). The GAG polysaccharides were
quantified by the carbazole assay with a glucuronic acid stan-
dard (65).
A group of recombinant HS-modifying enzymes, includ-
ing human C5-epimerase (NCBI accession number NM_
015554.1), hamster 2-O-sulfotransferase (GenBankTM acces-
sion number D88811.1), murine 6-O-sulfotransferase 1 (NCBI
accession number NM_015818.2), and murine 6-O-sulfotrans-
ferase 3 (NCBI accession number NM_015820.3), were used to
prepare HS polymers. The enzymes were each expressed as a
form of MBP fusions. The expression of these enzymes was
carried out in E. coli, and enzymes were purified by an amylose-
agarose column (New England Biolabs) as described previously
(5). A sulfo donor, PAPS, was prepared in house using amethod
published previously (66).
Syringe filters (0.2 m), Microcon YM-3 centrifugal filter
units with 3,000 molecular weight cutoff (MWCO), and Ami-
conUltra-15 3,000MWCO spin columns were purchased from
Millipore (Billerica, MA); the latter were washed three times
with deionized water before use. Vivapure Q mini H spin col-
umns were purchased from Sartorious Stedim Biotech (Bohe-
mia,NY). Dialysismembranes (1,000MWCO)were fromSpec-
trum Laboratories, Inc. (Houston, TX).
Unsaturated disaccharide standards of HS (0S, UA-GlcNAc;
NS, UA-GlcNS; 6S, UA-GlcNAc6S; 2S, UA2S-GlcNAc;
NS2S, UA2S-GlcNS; NS6S, UA-GlcNS6S; 2S6S, UA2S-
GlcNAc6S; TriS,UA2S-GlcNS6S whereUA is 4-deoxy--L-
threo-hex-4-enopyranosyluronic acid) were purchased from
Iduron (Cheshire, UK). E. coli expression and purification of
the recombinant Flavobacterium heparinum heparin lyases I
(heparin lyase), II, and III (heparin-sulfate lyase) (EnzymeCom-
mission (EC) numbers 4.2.2.7, 4.2.2.-, and 4.2.2.8, respectively)
were performed in our laboratory as described previously (67).
BaF3 cells expressing FGFR1c were generously provided by
Dr. David M. Ornitz of Washington University, St. Louis, MO.
FGF1 and FGF2, newborn bovine calf serum, penicillin/strep-
tomycin solution, sterile phosphate-buffered saline (PBS), and
Geneticin (G418) were purchased from Invitrogen. Interleukin
3 (IL3) was purchased from Peprotech (Rocky Hill, NJ). RPMI
1640 medium was purchased from Sigma. Sterile polystyrene
75-cm2 tissue culture treated flasks were purchased fromVWR
(Radnor, PA). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide (MTT) and Breathe EZ breathable membrane
were from Sigma.
Defined Polysaccharide Synthesis—Polysaccharides contain-
ing either (i) alternating NA blocks of GlcA-GlcNAc or NS
precursor blocks of GlcA-GlcNTFA repeating disaccharide
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units or (ii) an NA block with various specific sugar extensions
at the non-reducing termini were synthesized.
Initially, in all syntheses, a heparosan trisaccharide was
prepared from the successive transfer of UDP-GlcNAc (or
GlcNTFA) and UDP-GlcA, donors to GlcA-p-nitrophenyl gly-
coside, by a series of addition reactions catalyzed by PmHS2.
Here, the recombinant pmHS2 was constructed as an N-termi-
nal fusion to His6 using a PET-15b vector (Novagen) expressed
in BL21 star (DE3) cells (Invitrogen).
In subsequent block reactions, 0.5–2 mM heparosan trisac-
charide (GlcA-GlcNAc (or TFA)-GlcA-pNP) was used as an
acceptor to maintain a continuous block as desired. All block
reactions received 12–28mMUDP-GlcA and, depending on the
desired block, either 25 mM UDP-GlcNAc or 12–20 mM UDP-
GlcNTFA (for preparing the N- or S-domain, respectively) (20,
21). Reaction buffer contained 50–130mMHEPES, pH 7.2, and
1 mM MnCl2. Each reaction received 1 g/l purified MBP-
Chimera G enzyme. This enzyme, PmHS2(1–167)-PmHS1
(134–318)-PmHS2(353–651), was selected as the catalyst for
NS block polysaccharide synthesis because it exhibits at least a
10- and 2-fold higher specific activity using UDP-GlcNAc and
UDP-GlcNTFA when compared with PmHS2, respectively.
Also, Chimera G is roughly twice as acceptor-dependent as
PmHS2 due to a lower level of de novo synthesis (i.e. the initia-
tion with UDP-sugars only, not an exogenously supplied oligo-
saccharide). Each step was incubated at 30 °C for 16 h. After
polymerization was complete, the bulk of the enzyme was
removed by extraction with an equal volume of n-butyl alcohol
and vortexing followed by phase separation via centrifugation
at 14,000	 g for 5 min. The various HS precursors in the lower
aqueous phase were then purified as described later.
The molecular masses of each block section and the total
polymer were determined by a combination of polyacrylamide
gel/Alcian Blue staining analyses with size-defined standards
(22, 68), size exclusion chromatography coupled to multiangle
light scattering (29), and/or by LC-MS (68).
The precursor for HS 2was isolated from the extracted reac-
tionmixture using strong anion exchange (SAX) chromatogra-
phy on Sepharose Q resin (GE Healthcare) with an ammonium
formate step gradient (0.2 M wash for 10 column volumes and
then an elution with 0.7, 0.8, and 0.9 M for 1.5 column volumes
each). The pooled 0.7–0.9 M eluates were then frozen, and the
volatile salt was removed by repeated lyophilization fromwater.
It is important to note that the SAX step was used here instead
of paper chromatography (described later) for this long TFA-
containing block because polymers composed solely of this
more hydrophobic heparosan derivative migrated away from
the origin, thus complicating facile and efficient recovery.
The reaction mixture containing the precursor for HS poly-
saccharide1was used as the startingmaterial for targets3-8. To
create a more homogenous polymer with an equivalent and
defined non-reducing terminus, the repeating GlcNAc-GlcA-
pNP polysaccharide 1 product was further treated with a syn-
thase and one UDP-sugar and then purified to reduce its size
heterogeneity. First, the HS precursor was end-capped to
ensure all chains terminated with a GlcA residue via reaction
with5 molar eq of UDP-GlcA and 0.5 g/l wild-type MBP-
PmHS1 enzyme (27) to create a uniform population of NA
polysaccharide acceptor. Second, a SAX chromatography step
on Sepharose Q resin with a linear gradient (0.15 M wash for 5
column volumes and then a gradient to 1 M over 10 column
volumes in 25 min) followed by repeated lyophilization of the
target fractions fromwaterwas used. The end capping and SAX
steps were then repeated in tandem for another cycle. The final
central SAX peak was harvested to reduce the sample complex-
ity from the original 12 major species to 8 major species
(where “major” is defined as any species that is present at an
intensity level of at least 30%ormore of themost abundant peak
ion) as observed by LC-MS (69). The molecular weight of the
central peak polymer of resulting precursor 1 was 6,400 by
LC-MS.
The precursor for HS 3 (made in a reaction of the pre-SAX-
purified precursor for HS 1 as the acceptor for reactions with
UDP-GlcNTFA and UDP-GlcA donors) was isolated by pre-
parative descending paper chromatography (65:35 ethanol, 1 M
ammonium acetate, pH 5.5, development solvent with What-
man 3MM); the polysaccharide remains at the origin of the
paper strip, whereas any excess UDP-sugars and the UDP by-
product migrate substantially down the paper. The origin with
the target was cut out, air-dried, washed with ethanol, dried
again, and then eluted with water. The samples were then fro-
zen, and the volatile salt was removed by three cycles of lyoph-
ilization from water (typical overall yield,95%).
To create precursors forHS4-8, extensions ranging from five
to 11 monosaccharide units were sequentially added to the
non-reducing terminus of the SAX-polished, GlcA end-capped
precursor to HS 1 acceptor. These stepwise addition reactions
(e.g. first adding UDP-hexosamine, purification, and then add-
ing UDP-GlcA, etc.) used 1.2 molar eq of donor and a 1 g/l
concentration of the appropriate monofunctional Chimera G
catalyst (e.g. first the hexosamine transferase and then the
GlcA-transferase, etc.) under the same general reaction condi-
tions as described for the block polymers. The choice of hexos-
amine in any position of the chain was controlled by the UDP-
sugar, either UDP-GlcNAc or UDP-GlcNTFA, used in a given
step. At some steps, an intermediate polymer was split into two
parallel reactions that received either one or the other hexosa-
mine precursor, thus affording control of theN-sulfation status
of the terminal non-reducing sugar.
After each stepwise sugar addition, the target molecule was
isolated by batch mode paper chromatography; in this high
capacity method, the polysaccharide was spotted onto squares
of Whatman 3MM paper at 0.3 mg/cm2, air-dried, and
washed with eight changes of 65:35 ethanol, 1 M ammonium
acetate, pH 5.5 (15–45min each) to remove excessUDP-sugars
andUDP. The squares were thenwashedwith ethanol twice (10
min each), air-dried, and then eluted with water. The volatile
salt was removed by repeated lyophilization from water as
described before.
Detrifluoroacetylation andN-Sulfonation—Briefly, theN-tri-
fluoroacetylated block copolymer was dissolved in a solution of
1:1:0.5 MeOH:H2O:Et3N at a concentration of 1 mg/ml and
stirred overnight at room temperature to expose the amine
functionality protected by the TFA group. The de-N-trifluoro-
acetylated block copolymer was then loaded onto a 3,000
MWCOAmiconUltra spin unit and washed with distilled H2O
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three times at 14,000	 g for 10 min. The retentate containing
the de-N-trifluoroacetylated block copolymer was recovered
and lyophilized.
N-Sulfonation of block copolymers was then performed
according to a modified procedure from Maruyama et al. (70)
using NMe3SO3 as the sulfonating agent. The lyophilized de-
N-trifluoroacetylated polysaccharide was then dissolved in dis-
tilled H2O (1 mg/ml) at pH 7. Na2CO3 and NMe3SO3 were
then added in a 3:1 (w/w) ratio to polysaccharide (e.g. 3mg each
of Na2CO3 and NMe3SO3 for 1 mg of starting polymer) and
stirred for 12 h at 45 °C.A second equivalent portion ofNa2CO3
andNMe3SO3was then added to the reaction and stirred for an
additional 12 h at 45 °C. The reactionmixture was loaded into a
3,000MWCOAmiconUltra spin unit andwashedwith distilled
H2O three times at 14,000 	 g for 10 min. The retentate con-
taining the N-sulfonated polysaccharide was recovered and
lyophilized to afford a white fluffy powder.
Characterization of HS Block Copolymer Intermediates by
NMR—Analysis of the resulting block copolymers using PAGE
(56) confirmed that the polymer backbone remained intact fol-
lowing the de-N-trifluoroacetylation and N-sulfonation reac-
tions. The four block copolymers were also characterized by 1D
1H NMR spectroscopy after the chemical N-sulfonation step.
All samples were dissolved in 400 l of D2O (99.9%; Sigma-
Aldrich) and lyophilized three times to remove the exchange-
able protons. The samples were redissolved in 400 l of 99.9%
D2O and transferred to NMR microtubes. All NMR experi-
ments were performed at 298 K on a Bruker Advance II 600
MHz instrument with Topspin 2.1.6 software. 1Dl 1H spectra
were recorded for 32 scans.
EnzymaticO-Sulfonation—TheN-sulfonated polysaccharide
backbones were subjected to modifications by C5-epimerase,
2-O-sulfotransferase, and 6-O-sulfotransferase 1 and 6-O-sul-
fotransferase 3 to introduce IdoA residues, 2-O-sulfo groups,
and 6-O-sulfo groups, respectively. For the C5-epimerase (30)
and 2-O-sulfotransferase modifications, the reaction was car-
ried out in one-pot format to drive the reversible epimerization
reaction forward. Briefly, the backbone polysaccharides (0.1
mg/ml) were incubated with C5-epimerase (0.2 mg/ml) in a
buffer containing 1mMCaCl2 and 50mMMES, pH 7.0, at 37 °C.
After 30-min incubation, 2-O-sulfotransferase (0.1 mg/ml) and
PAPS (100 M) were added to the reaction mixture. The reac-
tion mixture was then incubated at 37 °C overnight. The prod-
uct was purified using DEAE-Sepharose column chromatogra-
phy as described previously (15). After 2-O-sulfonation, the
product (0.1mg/ml) was furthermodified with 6-O-sulfotrans-
ferase 1 (0.1 mg/ml) and 6-O-sulfotransferase 3 (0.1 mg/ml) in
50 mM MES, pH 7.0, PAPS (100 M) at 37 °C overnight. The
6-O-sulfonated products were then also purified through a
DEAE-Sepharose column.
Polysaccharide Purification—Each chemoenzymatically syn-
thesized HS sample was freeze-dried and then dissolved in
endotoxin-free water at a concentration of 2–8 mg/ml. Each
HS sample (0.8–3.1mg)was boundon theVivapureQMaxiH
mini SAX columns that had been pre-equilibrated with water
by centrifugation at 2,000 	 g for 10 min. Columns were
washed thrice with 400l of water and thrice with 400l of 0.2
M aqueous NaCl. The HS was then eluted by washing thrice
with 400 l of 1.0 M and thrice with 2.0 M aqueous NaCl. The
combined eluted samples were desalted by 1,000 MWCO dial-
ysis membranes and filtered through 0.2-m syringe filters.
The recovered samples were subjected to carbazole assay (65)
to measure each HS used to prepare stock solutions for chem-
ical and biological analyses.
Disaccharide Compositional Analysis of Precursor and Block
Copolymer Products by Using HPLC-MS—The disaccharide
compositions of block copolymers were analyzed by high per-
formance liquid chromatography-mass spectrometry (71).
Heparosan oligosaccharides (1–10g) were digested by adding
100 l of digestion buffer (50 mM ammonium acetate contain-
ing 2mM calcium chloride adjusted to pH7.0) and recombinant
heparin lyases I, II, and III (10 milliunits each in Tris-HCl
buffer, pH 7.0). The samples were digested at 37 °C overnight.
The reaction was terminated by eliminating the enzyme via
trapping in the retentate of 3,000 MWCO spin columns. The
filter units were washed twice with 300l of distilled water, and
the filtrates with disaccharides were collected, combined, and
lyophilized. The dried digested HS samples were AMAC-la-
beled by adding 20 l of 0.1 M AMAC in DMSO:acetic acid
(17:3, v/v) and incubating at room temperature for 10 min fol-
lowed by adding 20 l of 1 M aqueous sodium cyanoborohy-
dride and incubating for 1 h at 45 °C. A mixture containing all
eight disaccharide standards prepared at 12.5 ng/l was simi-
larly AMAC-labeled and used for each run as an external stan-
dard. After the AMAC labeling reaction, the samples were cen-
trifuged, and each supernatant was recovered.
For the disaccharide analysis of intermediate samples before
extensive purification, LC-MS analyses were performed on an
Agilent 1200 LC/MSD Instrument (Agilent Technologies, Inc.,
Wilmington, DE) equipped with a 6300 ion trap and a binary
pump. LC was performed at 45 °C using an Agilent Poroshell
120 ECC18 (2.7-m, 3.0 	 50-mm) column. Mobile phase A
was 50 mM ammonium acetate aqueous solution, and mobile
phase B was methanol. The flow rate was 300 l/min. The con-
centration ofmobile phase A increased from 5 to 45% during 10
min and then rose to 100% mobile phase B in the following 0.2
min, and a 4-min hold at 100% mobile phase B was applied to
elute all compounds. The mass spectrometer was operated in
negative ionization mode with a skimmer potential of40.0 V,
a capillary exit of40.0 V, and a source temperature of 350 °C.
Mass range of the spectrum was 300–900 m/z. Nitrogen (8
liters/min; 40 p.s.i.) was used as drying and nebulizing gas.
For disaccharide analysis of samples after purification, a tri-
ple quadrupole mass spectrometry system equipped with an
electrospray ionization source (Thermo Fisher Scientific, San
Jose, CA) was used as a detector. The onlineMS analysis was in
the multiple reaction monitoring mode. The conditions and
collision energies for the all of the disaccharide multiple reac-
tion monitoring transitions were as described before (16).
Cell Culture—BaF3 cells (a murine immortalized bone mar-
row cell line) were grown in RPMI 1640medium supplemented
with 10% newborn calf serum, 5 ml of penicillin/streptomycin
solution, 50 M -mercaptoethanol, and 400 g/ml G418 as
described previously (43, 54). In the absence of the FGF and
GAGcombination, BaF3 cells can be grownwith the addition of
5 ng/ml murine IL3 (Life Technologies) to the medium. Cells
HSDomains Required for FGF-FGFR Signaling
2506 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 292•NUMBER 6•FEBRUARY 10, 2017
were grown at 37 °C with 5% CO2 in T75 culture flasks. Cells
were passaged every 3 days with initial seeding densities of 2	
105 cells/ml.
Prior to use in the signaling assay, cells were centrifuged at
200	 g for 5min, spentmediumwas removed through vacuum
aspiration, and the cell pellet washed with 5 ml of IL3-free
RPMI 1640medium. The centrifugation andwashing stepwere
repeated four times to remove any residual IL3. The resulting
cell pellet was then used in the signaling assay below.
BaF3 Signaling Assay—RPMI 1640 medium with FGF1 or
FGF2 (5 M final) or no growth factor was added to the washed
BaF3 cell pellet to form a suspension (5	 106 cells/ml) that was
dispensed into a 96-well plate at 50,000 cells/well. Solutions of
the individual HS block copolymers or heparin (positive con-
trol) in PBS were added to obtain a final concentration of 2
g/ml. The negative control was PBS vehicle only. The plate
was incubated at 37 °C in 5% CO2 for 24 h. Each sample was
tested in triplicate wells.
Cell proliferation was measured with an MTT assay. Briefly,
40 l of a 2.5 mg/mlMTT solution was added to each well, and
incubated for 3 h. Then 100 l of 10% sodium dodecyl sulfate
(SDS) in 0.01 N HCl was added to each well and gently shaken
overnight to dissolve the formazan crystals. Optical density was
measured at 590 nm and at 690 nm as a control, the value of
which was subtracted from the absorbance at 590 nm to give a
background-corrected optical density. Optical density was cor-
related to cell count using a standard curve.
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